Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome

Trial Profile

A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Milnacipran (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 04 Jan 2019 Locations added as per EudraCT results (france, norway and romania were planned locations which is removed from CTP)
    • 15 Feb 2010 Results were published in the Journal of Rheumatology.
    • 02 Jul 2009 Results presented at 9th World Congress of Biological Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top